DIGITAL-ENVOY
14.7.2020 13:02:08 CEST | Business Wire | Press release
Digital Envoy, the inventor of IP intelligence, today announced that Jerrod Stoller has been appointed as its new President. Current President and CEO Bill Calpin has stepped back from his role and has been named Chairman of the Board. Co-founder and Executive Vice President Rob Friedman assumes a dual role with the addition of the Vice-Chairman title.
Stoller will assume day-to-day leadership of Digital Envoy, overseeing operations for all three business units: Digital Element , Digital Resolve and Gathr Lab . His focus will be driving product innovation and market strategy across all three business units to align all offerings even closer with the needs of current customers and the marketplaces at large.
“The Digital Envoy team has accomplished great things since our start in 1999, and I am extremely proud of the growth and success our teams have achieved during that time,” said Calpin. “Our accomplishments have always been reliant on the entire team and the common goal of making Digital Envoy bigger and better. As Jerrod joins the team, all of us will continue to play key roles in helping our company maximise its potential. Based on his past experiences and successes, it’s easy to understand the enthusiasm our entire team has for Jerrod joining and leading our company into the future.”
Before joining Digital Envoy, Stoller was CEO of eVestment where he had directed the sales, marketing, client success and business development activities of the organisation globally for almost 10 years. He took on the CEO role 18 months ago, while retaining his other duties. Before joining eVestment, Stoller was the Regional Manager of RSA, the Security Division of EMC, where he directed company performance into triple-digit growth. Prior to RSA, he held leadership roles with Datalex Transportation Enterprise Software, Siemens Business Services, TransQuest Business Consulting and NCR. Stoller holds a bachelor’s degree in finance from Purdue University.
“I am thrilled to assume this new role and incredibly excited about what we can accomplish together for the future,” said Stoller. “There is tremendous opportunity ahead for Digital Envoy. I look forward to continuing to support our clients at the highest levels as well as innovating new market and product strategies within our industry niches to solve real-world problems.”
All changes are effective immediately.
“As Digital Envoy has continued to grow, we felt the need to expand the team to help focus on both the operational and strategic needs of the company,” said Friedman. “For Bill and I, our new roles provide opportunities to continue to stay engaged in the business while also providing us more time to address some of the longer-term opportunities and partnerships available to us as the markets continue to change.”
About Digital Envoy
Launched in 1999, Digital Envoy introduced the concept of privacy-sensitive IP-based geolocation and IP intelligence, allowing businesses—from ad networks to publishers to websites to retailers and more—to harness the power of location and new intelligence about connected users for a multitude of mission-critical applications. Taking more of a background role, in 2005 Digital Envoy introduced two divisions to help best address the unique needs of its diverse audience segments and business applications: Digital Element, which was created to continue the legacy of providing global geolocation data and services that bring anytime, anywhere relevance and context to online and mobile initiatives; and Digital Resolve, which was launched to deliver solutions that proactively secure online accounts, information, transactions and interactions from login to logout. In 2019, Digital Envoy launched Gathr Lab to further expand on its two decades of location data expertise and provide anonymous, custom audience insights and segments at scale, across all devices. By helping clients to reach, understand and amplify their best audiences, Gathr Lab is leading change by committing to data anonymity and refreshing transparency rooted in location-based data science. Visit www.digitalenvoy.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom